|Articles|November 15, 2022
Utilizing Automated High-Throughput SEC Native Mass Spectrometry for mAb Screening
Author(s)Agilent Technologies
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Formulation Strategies, Tech Advances, Challenges, and Considerations in Novel Drug Delivery
2
FAQ: What You Need to Know About How Industry is Tackling CGT Bottlenecks
3
Drug Digest: Biopharma Landscape Evolves Through Strategic Alliances and Technology Integration
4
BioPharm Weekly News Roundup—Week of Nov. 24, 2025
5
